Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T21:58:47.144Z.
Calculation as of: 2026-10-06T21:58:47.144Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a8ce9bd0ffb1cb5d8a686ad50c5c0fc76176a0385911c5cc34bdb5d73fbb2f35
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$173.76M
Price/OCF Ratio
N/A
TTM Avg
21.38
3Y Avg
21.38
5Y Avg
21.38
Market Cap
$172.42M
Price/OCF Ratio
5.39
TTM Avg
8.72
3Y Avg
29.09
5Y Avg
22.81
Market Cap
$171.13M
Price/OCF Ratio
N/A
TTM Avg
357.25
3Y Avg
357.25
5Y Avg
357.25
Market Cap
$169.53M
Price/OCF Ratio
N/A
TTM Avg
32.12
3Y Avg
27.16
5Y Avg
27.16
Market Cap
$179.26M
Price/OCF Ratio
N/A
TTM Avg
28.65
3Y Avg
28.61
5Y Avg
28.61
Market Cap
$179.75M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Yarrow Bioscience Inc (YARW) | $174.27M | N/A | N/A | N/A | N/A |
| ProQR Therapeutics N.V. (PRQR)vs › | $173.76M | N/A | 21.38 | 21.38 | 21.38 |
| Organogenesis Holdings Inc. (ORGO)vs › | $172.42M | 5.39 | 8.72 | 29.09 | 22.81 |
| Precision BioSciences, Inc. (DTIL)vs › | $171.13M | N/A | 357.25 | 357.25 | 357.25 |
| Journey Medical Corporation (DERM)vs › | $169.53M | N/A | 32.12 | 27.16 | 27.16 |
| Oramed Pharmaceuticals Inc. (ORMP)vs › | $179.26M | N/A | 28.65 | 28.61 | 28.61 |
| MediWound Ltd. (MDWD)vs › | $168.92M | N/A | 7.42 | 7.42 | 7.42 |
| Compass Therapeutics, Inc. (CMPX)vs › | $179.75M | N/A | N/A | N/A | N/A |
| Cue Biopharma, Inc. (CUE)vs › | $168.10M | N/A | N/A | N/A | N/A |
| Canton Strategic Holdings Inc (CNTN)vs › | $180.47M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
